^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Gallbladder Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastric Cancer)
    New
    Excerpt:
    Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

    Excerpt:
    ...- Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use...
    Trial ID:
    NCT00004074
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Hematol Oncol
    Title:

    HER2/neu-directed therapy for biliary tract cancer

    Excerpt:
    Nine patients with gallbladder cancer...had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab)…All other cases had HER2/neu amplification or overexpression....In all these cases, trastuzumab was associated with partial response (n = 4), stable disease (n = 3), or complete response (n = 1).
    DOI:
    10.1186/s13045-015-0155-z